journal
Journals Therapeutic Advances in Neurol...

Therapeutic Advances in Neurological Disorders

https://read.qxmd.com/read/38751755/effectiveness-and-safety-of-telitacicept-for-refractory-generalized-myasthenia-gravis-a-retrospective-study
#1
JOURNAL ARTICLE
Jing Lin, Yue Li, Mengcui Gui, Bitao Bu, Zhijun Li
BACKGROUND: Refractory generalized myasthenia gravis (GMG) remains a substantial therapeutic challenge. Telitacicept, a recombinant human B-lymphocyte stimulator receptor-antibody fusion protein, holds promise for interrupting the immunopathology of this condition. OBJECTIVES: This study retrospectively assessed the effectiveness and safety of telitacicept in patients with refractory GMG. DESIGN: A single-center retrospective study. METHODS: Patients with refractory GMG receiving telitacicept (160 mg/week or biweekly) from January to September in 2023 were included...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38694710/erratum-to-guideline-for-the-management-of-myasthenic-syndromes-therapeutic-advances-in-neurological-disorders-vol-16-1-1-31-doi-10-1177-17562864231213240
#2
(no author information available yet)
[This corrects the article DOI: 10.1177/17562864231213240.].
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38685935/overview-of-systematic-reviews-comparing-endovascular-to-best-medical-treatment-for-large-vessel-occlusion-acute-ischaemic-stroke-an-umbrella-review
#3
REVIEW
Apostolos Safouris, Lina Palaiodimou, Aristeidis H Katsanos, Odysseas Kargiotis, Konstantinos I Bougioukas, Klearchos Psychogios, Tatiana Sidiropoulou, Stavros Spiliopoulos, Marios-Nikos Psychogios, Georgios Magoufis, Guillaume Turc, Georgios Tsivgoulis
BACKGROUND: The literature on endovascular treatment (EVT) for large-vessel occlusion (LVO) acute ischaemic stroke (AIS) has been rapidly increasing after the publication of positive randomized-controlled clinical trials (RCTs) and a plethora of systematic reviews (SRs) showing benefit compared to best medical therapy (BMT) for LVO. OBJECTIVES: An overview of SRs (umbrella review) and meta-analysis of primary RCTs were performed to summarize the literature and present efficacy and safety of EVT...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38654744/the-analysis-of-factors-affecting-medication-adherence-in-patients-with-myasthenia-gravis-a-cross-sectional-study
#4
JOURNAL ARTICLE
Yining Su, Xinxian Wang, Yuemeng Xing, Zhenni Wang, Hailing Bu, Xiaoyan Cui, Yunying Yang, Bingxing Cai
BACKGROUND: Clinically, patients with myasthenia gravis are generally treated with drugs to improve their physical condition, and poor medication adherence can hinder their recovery. Many studies have shown the importance of medication adherence for effective treatment. Various factors may affect a patient's medication adherence; however, studies concerning medication adherence in patients with myasthenia gravis are rare. OBJECTIVES: This study aimed to identify the factors related to medication adherence in patients with myasthenia gravis, and determine the possibility of predicting medication adherence...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38638673/long-term-safety-and-efficacy-of-zilucoplan-in-patients-with-generalized-myasthenia-gravis-interim-analysis-of-the-raise-xt-open-label-extension-study
#5
JOURNAL ARTICLE
James F Howard, Saskia Bresch, Constantine Farmakidis, Miriam Freimer, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J Kaminski, Angelina Maniaol, Renato Mantegazza, Masayuki Masuda, Richard J Nowak, Kumaraswamy Sivakumar, Marek Śmiłowski, Kimiaki Utsugisawa, Tuan Vu, Michael D Weiss, Małgorzata Zajda, Jos Bloemers, Babak Boroojerdi, Melissa Brock, Guillemette de la Borderie, Petra W Duda, Mark Vanderkelen, M Isabel Leite
BACKGROUND: Generalized myasthenia gravis (gMG) is a chronic, unpredictable disease associated with high treatment and disease burdens, with a need for more effective and well-tolerated treatments. OBJECTIVES: To evaluate the long-term safety, tolerability, and efficacy of zilucoplan in a mild-to-severe, acetylcholine receptor autoantibody-positive (AChR+) gMG population. DESIGN: Ongoing, multicenter, phase III open-label extension (OLE) study...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38638672/incidence-risk-factors-and-clinical-outcomes-of-acute-brain-swelling-associated-with-traumatic-acute-subdural-hematoma-a-retrospective-study-utilizing-novel-diagnostic-criteria
#6
JOURNAL ARTICLE
Shilong Fu, Haibing Liu, Guofeng Wang, Xiaofang Hu, Shousen Wang
BACKGROUND: Post-traumatic acute brain swelling (ABS) is a major cause of elevated intracranial pressure and thus mortality. The current definition of post-traumatic ABS has certain limitations, and there is limited information available regarding ABS associated with traumatic acute subdural hematoma (ASDH). OBJECTIVES: To investigate the incidence, risk factors, and clinical outcomes of ABS associated with traumatic ASDH. DESIGN: Retrospective study...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38638671/a-review-of-bruton-s-tyrosine-kinase-inhibitors-in-multiple-sclerosis
#7
REVIEW
Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiendl
Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of MS pathogenesis, along with mast cells, establishing the relevance of BTK inhibitors to diverse autoimmune conditions. First-generation BTK inhibitors are currently utilized in the treatment of B-cell malignancies and show efficacy in B-cell modulation. B-cell depleting therapies have shown success as disease-modifying treatments (DMTs) in MS, highlighting the potential of BTK inhibitors for this indication; however, first-generation BTK inhibitors exhibit a challenging safety profile that is unsuitable for chronic use, as required for MS DMTs...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38634003/a-retrospective-observational-study-on-characteristics-treatment-patterns-and-healthcare-resource-use-of-patients-with-myasthenia-gravis-in-england
#8
JOURNAL ARTICLE
Jordy van Enkhuizen, Jean Binns, April Betts, Fatemeh Saberi Hosnijeh, Myriam Alexander, Mark McCormack, Saiju Jacob
BACKGROUND: There are limited data on the real-world healthcare resource use (HCRU) and management costs of myasthenia gravis (MG) in England. OBJECTIVE: This study aims to assess the burden of disease for patients with MG in England. DESIGN: A retrospective, observational cohort study of adult patients diagnosed with MG, using data from the Hospital Episode Statistics data warehouse. METHODS: Patients with a first-ever recorded diagnosis of MG between 30 June 2015 and 30 June 2020 were followed up until 30 June 2021 or death, whichever occurred first...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38616782/treatment-algorithms-of-relapsing-multiple-sclerosis-an-exploration-based-on-the-available-disease-modifying-therapies-in-china
#9
REVIEW
Jun Guo, Jiayong Wu, Lihua Wang, Hongbo Liu, Xiaomu Wu, Huan Yang, Wenyu Li, Honghao Wang, Bitao Bu, Chunsheng Yang, Hongyu Zhou, Shougang Guo, Yinan Zhao, Zhanhang Wang, Chunyang Li, De-Cai Tian, Sheng Chen, Huiru Xue, Yanlin Zhang, Yongfeng Xu, Hui Liang, Zhe Wu, Yu Zhang, Qiang Dong, Jiawei Wang, Chao Quan
Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38616781/real-world-evidence-and-patient-preference-for-subcutaneous-versus-intravenous-natalizumab-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-initial-results-from-the-observational-sister-study
#10
JOURNAL ARTICLE
Ralf Gold, Stephan Schmidt, Florian Deisenhammer, Jeremias Motte, Nils Richter, Kirsi Taipale, Hans Christian Salmen, Christian Bohland, Ksenija Schirduan
BACKGROUND: The consideration of patient preference for a certain drug route of administration (RoA) plays an important role in promoting patient adherence in chronic diseases. Natalizumab is an established treatment for relapsing-remitting multiple sclerosis (RRMS) and can be administered as intravenous (IV) infusion or subcutaneous (SC) injection developed to enable a shorter and easier administration versus IV RoA. STUDY OBJECTIVES: Primary objective is to compare patients' preference for RoA and satisfaction with SC versus IV natalizumab at baseline and subsequent visits up to 12 months...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38596402/development-of-an-algorithm-for-identifying-paraneoplastic-ischemic-stroke-in-association-with-lung-pancreatic-and-colorectal-cancer
#11
JOURNAL ARTICLE
Rebecca Kassubek, Marc-Andre G R Winter, Jens Dreyhaupt, Mona Laible, Jan Kassubek, Albert C Ludolph, Jan Lewerenz
BACKGROUND: Paraneoplastic ischemic stroke has a poor prognosis. We have recently reported an algorithm based on the number of ischemic territories, C-reactive protein (CRP), lactate dehydrogenase (LDH), and granulocytosis to predict the underlying active cancer in a case-control setting. However, co-occurrence of cancer and stroke might also be merely incidental. OBJECTIVE: To detect cancer-associated ischemic stroke in a large, unselected cohort of consecutive stroke patients by detailed analysis of ischemic stroke associated with specific cancer subtypes and comparison to patients with bacterial endocarditis...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38585373/cladribine-tablets-after-treatment-with-natalizumab-cladrina-rationale-and-design
#12
JOURNAL ARTICLE
Peter V Sguigna, Rehana Z Hussain, Annette Okai, Kyle M Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A Lebson, Jeffrey Kaplan, Amber Salter, Navid Manouchehri, Olaf Stuve
BACKGROUND: Individual disease modifying therapies approved for multiple sclerosis (MS) have limited effectiveness and potentially serious side effects, especially when administered over long periods. Sequential combination therapy is a plausible alternative approach. Natalizumab is a monoclonal therapeutic antibody that reduces leukocyte access to the central nervous system that is associated with an increased risk of progressive multifocal leukoencephalopathy and disease reactivation after its discontinuation...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38572394/machine-learning-based-prediction-of-stroke-in-emergency-departments
#13
JOURNAL ARTICLE
Vida Abedi, Debdipto Misra, Durgesh Chaudhary, Venkatesh Avula, Clemens M Schirmer, Jiang Li, Ramin Zand
BACKGROUND: Stroke misdiagnosis, associated with poor outcomes, is estimated to occur in 9% of all stroke patients. OBJECTIVES: We hypothesized that machine learning (ML) could assist in the diagnosis of ischemic stroke in emergency departments (EDs). DESIGN: The study was conducted and reported according to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis guidelines. We performed model development and prospective temporal validation, using data from pre- and post-COVID periods; we also performed a case study on a small cohort of previously misdiagnosed stroke patients...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38566910/exploring-the-association-between-weight-loss-inducing-medications-and-multiple-sclerosis-insights-from-the-fda-adverse-event-reporting-system-database
#14
JOURNAL ARTICLE
Afsaneh Shirani, Anne H Cross, Olaf Stuve
BACKGROUND: Several studies have demonstrated that early childhood and adolescent obesity are risk factors for multiple sclerosis (MS) susceptibility. Obesity is thought to share inflammatory components with MS through overproduction of pro-inflammatory adipokines (e.g., leptin) and reduction of anti-inflammatory adipokines (e.g, adiponectin). Recently, drug repurposing (i.e. identifying new indications for existing drugs) has garnered significant attention. The US Food and Drug Administration Adverse Event Reporting System (FAERS) database serves not only as a resource for mining adverse drug reactions and safety signals but also for identifying inverse associations and potential medication repurposing opportunities...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38560408/treatment-switches-of-disease-modifying-therapies-in-people-with-multiple-sclerosis-long-term-experience-from-the-german-ms-registry
#15
JOURNAL ARTICLE
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C Salmen, Ksenija Schirduan, Tom P A Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K Zettl, Melanie Peters, Clemens Warnke
BACKGROUND: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice. OBJECTIVE: To compare switchers and non-switchers, characterize the first DMT switch and identify reasons and predictors for switching the first DMT. METHODS: Data on 2722 PwMS from the German MS Registry were retrospectively analyzed regarding sociodemographic/clinical differences between 1361 switchers (PwMS discontinuing the first DMT) and non-switchers matched according to age, sex, and observation period...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38560407/serum-neurofilament-light-chain-correlations-in-patients-with-a-first-clinical-demyelinating-event-in-the-reflex-study-a-post-hoc-analysis
#16
JOURNAL ARTICLE
Jens Kuhle, David Leppert, Giancarlo Comi, Nicola de Stefano, Ludwig Kappos, Mark S Freedman, Andrea Seitzinger, Sanjeev Roy
BACKGROUND: In REFLEX, subcutaneous interferon beta-1a (sc IFN β-1a) delayed the onset of multiple sclerosis (MS) in patients with a first clinical demyelinating event (FCDE). OBJECTIVES: This post hoc analysis aimed to determine whether baseline serum neurofilament light (sNfL) chain can predict conversion to MS and whether correlations exist between baseline sNfL and magnetic resonance imaging (MRI) metrics. METHODS: sNfL was measured for 494 patients who received sc IFN β-1a 44 μg once weekly (qw; n  = 168), three times weekly (tiw; n  = 161), or placebo ( n  = 165) over 24 months...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38532803/sex-differences-in-multiple-sclerosis-relapse-presentation-and-outcome-a-retrospective-monocentric-study-of-134-relapse-events
#17
JOURNAL ARTICLE
Pauline Thränhardt, Admirim Veselaj, Christoph Friedli, Franca Wagner, Stefanie Marti, Lara Diem, Helly Hammer, Piotr Radojewski, Roland Wiest, Andrew Chan, Robert Hoepner, Anke Salmen
BACKGROUND: Reporting of sex-specific analyses in multiple sclerosis (MS) is sparse. Disability accrual results from relapses (relapse-associated worsening) and independent thereof (progression independent of relapses). OBJECTIVES: A population of MS patients during relapse treated per standard of care was analyzed for sex differences and short-term relapse outcome (3-6 months) as measured by Expanded Disability Status Scale (EDSS) change. DESIGN: Single-center retrospective study...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38532802/patisiran-exposure-in-early-pregnancy-a-case-report
#18
Valentin Loser, Thomas Baumgartner, Hélène Legardeur, Alice Panchaud, Marie Théaudin
We describe here the first case of exposure to patisiran treatment, a small interfering RNA molecule, during early pregnancy of a 36-year-old woman with symptomatic hereditary transthyretin-related amyloidosis. There were no major complications during pregnancy and delivery, except for a postpartum hemorrhage due to uterine atony. Vitamin A levels had to be closely monitored during pregnancy, and vitamin A substitution adapted accordingly. There was no sign of minor or major congenital abnormalities of the baby...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38532801/improved-visualization-of-median-ulnar-nerves-and-small-branches-in-the-wrist-and-palm-using-contrast-enhanced-magnetic-resonance-neurography
#19
JOURNAL ARTICLE
Jiamin Kang, Wenjun Wu, Xiangchuang Kong, Yu Su, Dingxi Liu, Chungao Li, Nan Gao, Youzhi Wang, Chuansheng Zheng, Yuxiong Weng, Lixia Wang
BACKGROUND: Magnetic resonance imaging of peripheral nerves in the wrist and palm is challenging due to the small size, tortuous course, complex surrounding tissues, and accompanying blood vessels. The occurrence of carpal palmar lesions leads to edema, swelling, and mass effect, which may further interfere with the display and identification of nerves. OBJECTIVE: To evaluate whether contrast-enhanced magnetic resonance neurography (ceMRN) improves the visualization of the morphology and pathology of the median, ulnar nerves, and their small branches in the wrist and palm...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38525490/comparative-efficacy-of-ofatumumab-versus-oral-therapies-for-relapsing-multiple-sclerosis-patients-using-propensity-score-analyses-and-simulated-treatment-comparisons
#20
JOURNAL ARTICLE
Nicholas Riley, Christopher Drudge, Morag Nelson, Anja Haltner, Michael Barnett, Simon Broadley, Helmut Butzkueven, Pamela McCombe, Anneke Van der Walt, Erin O Y Wong, Martin Merschhemke, Nicholas Adlard, Rob Walker, Imtiaz A Samjoo
BACKGROUND: Evidence from network meta-analyses (NMAs) and real-world propensity score (PS) analyses suggest monoclonal antibodies (mAbs) offer a therapeutic advantage over currently available oral therapies and, therefore, warrant consideration as a distinct group of high-efficacy disease-modifying therapies (DMTs) for patients with relapsing multiple sclerosis (RMS). This is counter to the current perception of these therapies by some stakeholders, including payers. OBJECTIVES: A multifaceted indirect treatment comparison (ITC) approach was undertaken to clarify the relative efficacy of mAbs and oral therapies...
2024: Therapeutic Advances in Neurological Disorders
journal
journal
42104
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.